# Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

> **NCT04879121** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (estimated)

## Conditions studied

- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **DRUG:** Larotrectinib Sulfate

## Key facts

- **NCT ID:** NCT04879121
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2027-11-11
- **Final completion:** 2027-11-11
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04879121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04879121, "Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04879121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*